LX-4211

Use

Sotagliflozin is a dual SGLT-1/SGLT-2 inhibitor which is currently under development by Lexicon Pharmaceuticals (phase III). It follows a similar strategy to ertugliflozin, i.e. aryl addition on an acyclic precursor. The synthesis starts from L-xylose 53, and the aryl moiety (same aryl moiety as for dapagliflozin) is introduced on an amide derivative (morpholine amide 54) via Grignard addition. A subsequent transformation leads to the sotagliflozin (Scheme 10). The overall yield of the synthesis is around 30%. Sotagliflozin synthesis Sotagliflozin is a dual SGLT-1/SGLT-2 inhibitor which is currently under development by Lexicon Pharmaceuticals (phase III). It follows a similar strategy to ertugliflozin, i.e. aryl addition on an acyclic precursor. The synthesis starts from L-xylose 53, and the aryl moiety (same aryl moiety as for dapagliflozin) is introduced on an amide derivative (morpholine amide 54) via Grignard addition. A subsequent transformation leads to the sotagliflozin (Scheme 10). The overall yield of the synthesis is around 30%. Sotagliflozin synthesis

LX-4211 manufacturers

• LX-4211
• 
• US $999.00-900.00 / kg
• 2024-08-26
• CAS:1018899-04-1
• Min. Order: 0.0010000000474974513kg
• Purity: 99%
• Supply Ability: 5000

• LX-4211
• 
• US $1.00 / g
• 2024-08-23
• CAS:1018899-04-1
• Min. Order: 1g
• Purity: 98%
• Supply Ability: 1000

• Sotagliflozin,LX-4211, LP-802034, LX4211, LP802034
• 
• US $0.00-0.00 / kg
• 2024-05-09
• CAS:1018899-04-1
• Min. Order: 1kg
• Purity: 99%，single impurity＜0.1
• Supply Ability: 1 ton